🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The objective of this study is to evaluate in a 3 +3 design, the safety of ...
Status
Completed
Location
University of California, Moores Cancer Center
Start Date
2015-12
Trial ID
NCT02643550
Treatments Being Tested
The study is intended to assess the safety and efficacy of perioperative tr...
Status
Recruiting
Location
Research Site
Start Date
2022-04-14
Trial ID
NCT05061550
Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refr...
Status
Terminated
Location
The Ohio State University Wexner Medical Center
Start Date
2015-11-09
Trial ID
NCT02557516
Treatments Being Tested
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expa...
Status
Withdrawn
Location
Institut Jules Bordet
Start Date
2017-07-20
Trial ID
NCT03307941
Treatments Being Tested
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectivenes...
Status
Completed
Location
Research Site
Start Date
2019-03-08
Trial ID
NCT03794544
Treatments Being Tested
This study will determine the Maximal Tolerated Dose if any and the recomme...
Status
Unknown
Location
Institut Paoli Calmettes
Start Date
2016-11-28
Trial ID
NCT02921685
Treatments Being Tested
Research Hypothesis Lung cancer is the leading cause of cancer-related mort...
Status
Unknown
Location
Assistance Publique Hopitaux de Marseille
Start Date
2019-10-08
Trial ID
NCT03833440
Columbia 2 is a Phase 2 platform study to evaluate the safety and efficacy ...
Status
Withdrawn
Location
Multiple Locations
Start Date
2020-10-01
Trial ID
NCT04145193
This phase I trial studies the safety of adding durvalumab to accelerated h...
Status
Completed
Location
Grady Health System
Start Date
2019-10-28
Trial ID
NCT03801902
The purpose of this study is to compare the clinical activity of durvalumab...
Status
Completed
Location
Research Site
Start Date
2018-12-19
Trial ID
NCT03822351
Treatments Being Tested